Author: acn

HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - To promote Hong Kong’s business advantages and enhance trade and economic cooperation between Hong Kong and Thailand and the wider ASEAN region, Prof Frederick Ma, Chairman of the Hong Kong Trade Development Council (HKTDC), visited Bangkok and met with senior government and business leaders.Prof Ma spoke on a panel at the Singapore Regional Business Forum organised by the Singapore Business Federation. He said, “Businesses are diversifying amid the changing landscape. Asia remains a major engine for economic growth, underpinned by the rise of emerging markets, like ASEAN and the Middle East. China, with its industrial base and vast population, is a stabilising force in an ever-changing world. And Hong Kong, given its superconnector and super value-adder roles, is a dynamic platform linking Mainland China with the world.”Aside from the event, Prof Ma met with Chantawit Tantasith, Deputy Minister of Commerce of Thailand, and Dhanin Chearavanont, Senior Chairman of Charoen Pokphand Group, to exchange views on deepening Hong Kong-Thailand trade and economic cooperation.Prof Ma noted: “Thailand is an important trade and investment partner for Hong Kong. I am delighted that I had the opportunity to exchange insights with the Ministry of Commerce and leading enterprises in Thailand as well as political and business leaders from Singapore to further strengthen the economic ties between Hong Kong and Thailand and the wider ASEAN region.”As a statutory body, the HKTDC promotes, assists and develops Hong Kong’s external trade, while supporting Hong Kong businesses to tap into the opportunities in ASEAN. The HKTDC’s flagship events, such as the Asian Financial Forum and the Belt and Road Summit, serve as ideal platforms to highlight the latest developments and opportunities in Hong Kong as well as the city’s advantages in professional services, while facilitating cross-regional collaboration. Photo Download: http://bit.ly/4lBDJFAHKTDC Chairman Prof Frederick Ma meets with Chantawit Tantasith, Deputy Minister of Commerce of ThailandHKTDC Chairman Prof Frederick Ma meets with Dhanin Chearavanont, Senior Chairman of Charoen Pokphand GroupProf Frederick Ma, Chairman of HKTDC, discusses business resilience in Asia and promotes Hong Kong business advantages at the Singapore Regional Business Forum in BangkokPlease contact the HKTDC’s Communication & Public Affairs Department:Sam HoTel: (852) 2584 4569Email: sam.sy.ho@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

Results Summary- Total revenue increased by 8% to HK$2,800 million, among which the revenue from Hong Kong increased by 9% to HK$1,600 million while the revenue from Mainland China increased by 9% to HK$700 million – both markets recorded growths- Revenue from the jewellery segment increased markedly by 13% to HK$1,100 million, among which gold products accounted for over 75% of the revenue from the jewellery segment- Gross profit rose by 8% to HK$800 million; gross profit margin remained resilient at 30.1%- Adjusted EBITD1 increased to HK$300 million and net profit rose by 5% to HK$200 million- As at 30 June 2025, bank balances and cash on hand amounted to over HK$1,500 million (31 December 2024: HK$950 million), without any bank borrowings and was in a net cash position, hence its net gearing ratio was zero, indicating a very healthy financial position- Successfully partnered with Mr. Chan Sai Cheong, strives to expand the jewellery business in Mainland China under “Emperor Jewellery”, and has already drawn up a preliminary roadmap for store expansions, with an initial target of 600 stores in Mainland China in the next five years; enables the jewellery business to become its future growth driver under the solid foundation of its watch business- Opened a Patek Philippe flagship store at a prime location in Central, Hong Kong, strengthening its market positionHONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Emperor Watch & Jewellery Limited (“Group” or “Emperor W&J”) (Stock code: 887), a leading retailer of European-made watches and jewellery products, announced its interim results for the six months ended 30 June 2025 (“Period”).In spite of market uncertainties and challenging business environment, the Group’s total revenue grew by 7.6% to HK$2,794 million (2024: HK$2,597 million) during the Period. Revenue from Hong Kong increased by 8.8% to HK$1,594 million (2024: HK$1,465 million), accounting for 57.1% (2024: 56.4%) of the total revenue, and the revenue from Mainland China increased by 8.7% to HK$723 million (2024: HK$665 million), accounting for 25.9% (2024: 25.6%) of the total revenue. In terms of revenue by product segment, the revenue from the watch segment increased by 4.2% to HK$1,700 million (2024: HK$1,632 million), accounting for 60.8% (2024: 62.8%) of the total revenue, and the revenue from the jewellery segment increased markedly by 13.4% to HK$1,094 million (2024: HK$965 million), accounting for 39.2% (2024: 37.2%) of the total revenue, among which gold products accounted for 75.2% (2024: 77.0%) of the revenue from the jewellery segment.The Group’s gross profit increased by 7.7% to HK$840 million (2024: HK$780 million) with gross profit margin remained resilient at 30.1% (2024: 30.0%). The Group’s net profit increased by 4.9% to HK$194 million (2024: HK$185 million) during the Period. Basic earnings per share was HK2.73 cents (2024: HK2.72 cents). The Board declares an interim dividend of HK0.55 cent (2024: HK0.65 cent) per share.As at 30 June 2025, bank balances and cash on hand of the Group amounted to HK$1,508 million (31 December 2024: HK$950 million), without any bank borrowings (31 December 2024: zero) and was in a net cash position, hence its net gearing ratio was zero (31 December 2024: zero), indicating a healthy financial position.During the Period, the Group successfully partnered with Mr. Chan Sai Cheong (“Mr. Chan”), an influential and highly respected jewellery industry veteran with over 40 years of experience, regarding strategic development of the Group’s jewellery business in Mainland China. The Group has drawn up a preliminary roadmap for store expansions in Mainland China, with an initial target of 600 stores in the next five years, opening in phases. During the first phase, the focus will be on opening stores targeting mid-to-high-end market segments in established first-tier and new first-tier cities; this will be followed by an emphasis on stores in second-tier cities, targeting mid-market segment.As at 30 June 2025, the Group had a total of 73 stores in Hong Kong, Macau, Mainland China, Singapore and Malaysia. During the Period, the Group opened two new jewellery stores, in Hong Kong and Macau. Additionally, a Patek Philippe flagship store and a Tudor watch boutique were opened in Hong Kong and Chongqing in Mainland China, respectively. Subsequent to the Period, the Group opened a jewellery store in Hangzhou, Mainland China.Ms. Cindy Yeung, Chairperson of Emperor W&J, said, “With the ongoing pick-up in foot traffic after the resumption of the multiple-entry Individual Visit Scheme for Shenzhen permanent residents, and the tourism blueprint launched by the Hong Kong government, the Group is confident that the overall retail market will further regain its growth momentum. The Patek Philippe flagship store that was recently opened by the Group in Hong Kong will further enhance the Group’s competitive edge in the luxury watch retail market and strengthens its market leading position.”Ms. Yeung concluded, “The Group expects that gold jewellery, as an alternative form of investment, will continue being well received by Chinese consumers, given the volatile property and stock markets. The Group considers the establishment of the strategic partnership with Mr. Chan is a valuable opportunity for expanding its jewellery business in Mainland China. We will effectively expand its retail network footprint with diversified market segmentation strategies, thereby capturing a substantial share of the enormous opportunities in the Mainland China market.”Financial Highlights For the six months ended 30 JuneChanges2024HK$ million2025HK$ millionTotal revenue2,5972,794+ 7.6%Gross profit780840+ 7.7%Gross profit margin30.0%30.1%+ 0.1ppAdjusted EBITD [1]282297+ 5.3%Net profit185194+ 4.9%Basic earnings per shareHK2.72 centsHK2.73 cents+ 0.4%[1] Adjusted EBITD represents earnings before interest, tax and depreciation charge on the self-owned flagship store, which reflects the Group’s core operating performanceAbout Emperor Watch & Jewellery LimitedWith long establishment history of over 80 years in Hong Kong since 1942, Emperor W&J (887.HK) is a leading retailer principally engages in the sale of European-made internationally renowned watches, and jewellery products under its own brand, “Emperor Jewellery”. Through its comprehensive watch dealership, unique marketing campaigns and extensive retail network at prime locations in Hong Kong, Macau, Mainland China, Singapore and Malaysia, Emperor W&J established a strong brand image amongst its target customers ranging from middle to high income groups worldwide. In recognition of its efforts in investor relations communications, Emperor W&J was granted with “Best IR Company” (Small Cap), “Best IR Team” (Small Cap) and “Best Investor Presentation Material” (Small cap) in HKIRA Investor Relations Awards 2025 by the Hong Kong Investor Relations Association. For more information, please visit its website: www.EmperorWatchJewellery.com.Investor/Media EnquiriesAnna LukGroup Investor Relations DirectorTel: +852 2835 6783Email: annaluk@emperorgroup.comJanice AuGroup Investor Relations ManagerTel: +852 2835 6799Email: janiceau@emperorgroup.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SHENZHEN, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Following its highly anticipated global reveal earlier this month, Level Infinite will launch the game's 1st Closed Beta in early November. Players can be the first to get a hands-on with the game this week at gamescom 2025 in Cologne from 20th to 24th August. Rust Mobile delivers a full-scale open-world survival gameplay that millions of fans know and love, optimized for mobile devices.Officially licensed by Facepunch Studios, Rust Mobile stays true to the spirit of the original while introducing a fresh way to survive on the go. From gathering resources and building fortified bases to ruthless PvP combat and the tension of trust and betrayal, the mobile version captures the essence of Rust. Players will have the opportunity to experience all the excitement the game offers firsthand at both gamescom and through the upcoming Closed Beta Test.Rust Mobile at Gamescom 2025Attendees can find the Rust Mobile booth in Hall 06.1 - C-051G, where they'll get hands-on time with the game and take part in activities designed to bring the world of Rust to life. Activities include interacting with themed props, immersing themselves in the booth environment.Every participant will also earn a spin on the Loot Wheel, with the chance to win exclusive Gamescom 2025 memorabilia, including limited-edition posters and tote bags.1st Closed Beta Coming This NovemberRust Mobile's 1st Closed Beta will launch in early November 2025, inviting 30,000 players from North America, Western Europe, and select regions in Asia.The beta will feature four language options English, Japanese, Traditional Chinese, and Thai and will support iOS, Android, and tablet devices, ensuring players can experience the game on their platform of choice.Registration for the Closed Beta Test is now open at www.rustmobile.comFor more information about Rust Mobile or to pre-register, head to rustmobile.com, or follow the game on X, and YouTube. For gamescom opening times visit www.gamescom.global.About Level InfiniteLevel Infinite is Tencent's global games brand, dedicated to delivering engaging and original gaming experiences to a worldwide audience, whenever and wherever they choose to play. The brand also provides a wide range of services and resources to a network of developers and partner studios around the world to help them unlock the potential of their games. Level Infinite is both publisher of breakout hit games like PUBG MOBILE, Honor of Kings and Goddess of Victory: NIKKE and a collaborative partner in games such as Dune: Awakening from Funcom, Warhammer 40K: Darktide and many more. To learn more about Level Infinite, visit www.levelinfinite.comContact InformationKirsty EndfieldSwipe Right PRtencent@swiperight.ggSOURCE: Level Infinite Copyright 2025 ACN Newswire via SeaPRwire.com.

业绩摘要- 本期间的总收入上升8%至28亿港元，其中来自香港的收入上升9%至16亿港元，而来自中国内地的收入上升9%至7亿港元，两地均录得增长- 珠宝分部的收入显著上升13%至11亿港元，当中黄金产品占珠宝分部的收入超过7成半- 毛利增加8%至8亿港元；毛利率为30.1%，表现呈抗跌力- 经调整EBITD1上升至3亿港元，净利润增加5%至2亿港元- 于2025年6月30日，银行结余及手头现金为超过15亿港元(2024年12月31日：9.5亿港元)，没有任何银行借贷，并处于净现金状况，因此净负债比率为零，反映财务状况非常健康- 成功伙拍陈世昌先生，致力扩展「英皇珠宝」于中国内地之珠宝业务，并已拟定初步开店路线图，初期目标是于未来五年分阶段于中国内地开设600间店铺。在其具韧性的钟表业务基础上，务求珠宝业务成为未来增长动力- 于香港中环黄金地段开设了一间百达翡丽旗舰店，进一步巩固市场地位香港，2025年8月20日 - (亚太商讯 via SeaPRwire.com) - 欧洲制钟表及珠宝首饰之零售商翘楚－英皇钟表珠宝有限公司(「本集团」或「英皇钟表珠宝」)(股份编号：887)公布其截至2025年6月30日止六个月(「本期间」)之中期业绩。纵使市场存在不明朗因素及营商环境充满挑战，本集团于本期间的总收入增加7.6%至27.9亿港元(2024年：26.0亿港元)。来自香港的收入增加8.8%至15.9亿港元(2024年：14.7亿港元)，占总收入57.1%(2024年：56.4%)，而来自中国内地的收入增加8.7%至7.2亿港元(2024年：6.7亿港元)，占总收入25.9% (2024年：25.6%)。按产品分部划分的收入而言，钟表分部的收入上升4.2%至17.0亿港元(2024年：16.3亿港元)，占总收入60.8% (2024年：62.8%)，而珠宝分部的收入显著增加13.4%至10.9亿港元(2024年：9.7亿港元)，占总收入39.2% (2024年：37.2%)，当中黄金产品占珠宝分部的收入约75.2% (2024年：77.0%)。本集团的毛利增加7.7%至8.4亿港元(2024年：7.8亿港元)，毛利率为30.1% (2024年：30.0%)，表现呈抗跌力。本集团于本期间的净利润增加4.9%至1.94亿港元(2024年：1.85亿港元)。每股基本盈利为2.73港仙(2024年：2.72 港仙)。董事会宣派中期股息每股0.55港仙(2024年：0.65 港仙)。于2025年6月30日，本集团之银行结余及手头现金为15.1亿港元(2024年12月31日：9.5亿港元)，没有任何银行借贷(2024年12月31日：零)并处于净现金状况，因此净负债比率为零(2024年12月31日：零)，显示健康的财务状况。于本期间，本集团就其于中国内地珠宝业务之策略性发展成功伙拍陈世昌先生（「陈先生」）。陈先生为一位于珠宝行业具影响力且备受推崇的资深人士，拥有超过40年的经验。本集团已初步拟定于中国内地扩展店铺的路线图，初期目标是于未来五年分阶段开设600 间店铺。于第一阶段，开店的重点会落在成熟的一线城市及新一线城市，面向中高端市场；后续开店将侧重于二线城市，面向中端市场。于2025年6月30日，本集团于香港、澳门、中国内地、新加坡及马来西亚营运共73间店铺。于本期间，本集团于香港及澳门新开设两间珠宝店，另外亦分别于香港及中国内地重庆开设一间百达翡丽旗舰店及一间帝舵表钟表专卖店。本期间后，本集团于中国杭州开设一间珠宝店。英皇钟表珠宝主席杨諾思女士表示︰「随着深圳户籍居民一签多行个人游计划恢复后人流持续回升，加上香港政府推行的旅游业蓝图，本集团有信心整体零售市场将进一步重拾增长动力。本集团近期于香港开业的百达翡丽旗舰店，将进一步提升本集团于名贵钟表零售市场的竞争优势，并巩固其市场领先地位。」杨女士总结道︰「鉴于物业及股票市场波动，本集团预期作为另类投资的黄金珠宝将继续受中国消费者欢迎。本集团认为与陈先生建立战略合作伙伴关系，将为扩展其于中国内地之珠宝业务带来宝贵机会。我们将以多元化市场细分策略，有效地扩大其零售网络布局，从而在中国内地市场的庞大商机中抢占重大份额。」财务亮点 截至6月30日止六个月变动2024年百万港元2025年百万港元总收入2,5972,794+ 7.6%毛利780840+ 7.7%毛利率30.0%30.1%+ 0.1百份点经调整EBITD[1]282297+ 5.3%净利润185194+ 4.9%每股基本盈利2.72港仙2.73港仙+ 0.4%[1]经调整EBITD为利息、税项及自家拥有旗舰店的折旧费用前之盈利，以反映本集团之核心营运表现关于英皇钟表珠宝有限公司作为零售商翘楚，英皇钟表珠宝(887.HK)自1942年在香港开业至今已有超过80年悠久历史，业务包括销售享誉国际之欧洲制腕表及旗下「英皇珠宝」品牌之珠宝首饰。凭借其代理齐全的钟表品牌、独特的市场推广策略以及遍布香港、澳门、中国内地、新加坡及马来西亚黄金地段的广泛零售网络，英皇钟表珠宝在全球各地中高收入人士的目标顾客群中已建立稳固的品牌形象。于香港投资者关系协会颁发的2025年香港投资者关系大奖中，英皇钟表珠宝荣获「最佳投资者关系公司-小型股」、「最佳投资者关系团队-小型股」及「最佳投资者关系素材-小型股」。有关详细资料，请浏览其网站︰www.EmperorWatchJewellery.com。投资者/媒体查询陆文静集团投资者关系总监电话︰+852 2835 6783电邮：annaluk@emperorgroup.com区雪莹集团投资者关系经理电话电话︰+852 2835 6799电邮：janiceau@emperorgroup.com Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月21日 - (亚太商讯 via SeaPRwire.com) - 比优集团控股有限公司（「比优集团」或「本公司」，连同其附属公司统称「本集团」，股份代号：09893.HK）欣然宣布，近日集团获国内领先金融数据平台Wind提升ESG评级，由BB级跃升至A级，跻身行业前列，充分体现集团在可持续发展方面的卓越表现。Wind ESG评级A级代表企业在环境、社会及管治维度的综合实力处于行业头部领先水平。据Wind最新评级结果显示，在基础化工行业中，获得A级的企业仅占约19.35%，显示出比优集团在ESG管理及实践方面已居于行业上游。本集团ESG评级实现从BB至A的两级跨越，主要得益于系统性的可持续发展举措。根据比优集团最新发布的《2024/2025年度环境、社会及管治报告》，集团在环境层面全面落实大气污染物减排、温室气体管控、废弃物资源化及生态修复等项目，大力推进绿色矿山建设与社会责任履行；在社会维度，持续完善安全生产体系与员工健康保障，强化产品质量与供应链合规管理，特别是在"一带一路"沿线国家推行本地化运营，积极践行社区共建与企业公民责任；在管治维度，集团建立了系统、全面的合规管理制度和风险控制流程，通过常态化的审计监察与员工培训，严守商业道德底线，积极预防舞弊与腐败行为，并设立了对董事会直接负责的ESG工作组，将可持续发展深度融入公司治理核心。Wind作为中国金融信息服务业最具权威性与影响力的平台之一，其ESG评级体系依托强大的数据治理能力与深厚的行业积累，构建了涵盖大量定量与定性指标的科学评估框架。该体系接轨国际标准，深度融合中国本土信息披露政策与企业实践，Wind ESG评级结果与底层数据已全面覆盖A股、港股上市公司，公募信用债发债主体及国内公募基金。本次比优集团ESG评级的上调，反映了其在治理结构优化、环境与社会绩效提升、以及信息披露质量方面获得第三方评级机构的高度认可。董事会相信，此次评级的跃升不仅体现了集团在可持续发展方面的扎实进展，也将进一步强化投资者的信心。未来，比优集团将继续深化绿色运营、推进技术革新，持续提升ESG管理的透明度，积极践行可持续发展理念，推动实现高质量的企业成长。关于比优集团控股有限公司比优集团控股有限公司（主板股票代号：09893.HK）是一家专注于民用爆炸品的生产销售、爆破工程服务，矿山资源开发和勘探业务的领军企业。集团在国内市场占据重要份额，并在中亚等全球市场积极拓展业务。公司网址：http://www.pizugroup.com Copyright 2025 亚太商讯 via SeaPRwire.com.

深圳, 2025年8月20日 - (亚太商讯 via SeaPRwire.com) - 在本月早些时候备受期待的全球首秀之后，Level Infinite 将于11月初开启《Rust Mobile》首次封闭测试。玩家们可以在 2025 年 8 月 20 日至 24 日于科隆举办的 gamescom 上，率先亲身体验这款游戏。《Rust Mobile》将经典的开放世界生存玩法完整呈现，并针对移动设备进行了优化，让数百万粉丝熟悉并热爱的体验随时随地都能上手。本作由 Facepunch Studios 官方授权，在忠实还原原作精神的同时，也为移动端带来全新的生存方式。从收集资源、建造坚固基地，到残酷的 PvP 战斗，以及伴随信任与背叛而来的紧张氛围，移动版完整呈现了《Rust》的核心精髓。玩家不仅能够在 gamescom 上率先感受游戏的魅力，还可通过即将到来的封闭测试进一步体验其独特乐趣。《Rust Mobile》亮相 2025 科隆游戏展参展观众可前往 06.1 展馆 - C-051G 展位，在这里亲身体验游戏，并参与一系列将《Rust》世界带入现实的特色活动。活动包括与主题道具互动、沉浸式感受展位环境等。每位参与者都将获得一次转动“战利品转盘”的机会，有机会赢取 2025 科隆游戏展独家纪念品，包括限量版海报和环保袋。首次封闭测试将于今年11月开启《Rust Mobile》首次封闭测试将于 2025 年 11 月初上线，届时将邀请来自北美、西欧及部分亚洲地区的 30,000 名玩家参与。本次测试将提供四种语言版本：英语、日语、繁体中文和泰语，并支持 iOS、Android 及平板设备，确保玩家能够在自己熟悉的平台上畅玩游戏。封闭测试现已开放注册，玩家可前往 www.rustmobile.com 报名。欲了解更多有关《Rust Mobile》的信息或进行预注册，请访问 rustmobile.com，或关注游戏的 X 账号与 YouTube 频道。有关科隆游戏展开馆时间，请访问 www.gamescom.global。关于 Level InfiniteLevel Infinite 是腾讯旗下的全球游戏品牌，致力于随时随地为全球玩家带来引人入胜且独具特色的游戏体验。该品牌还为全球范围内的开发者和合作工作室提供多种服务与资源，帮助他们释放游戏潜力。Level Infinite 既是《PUBG MOBILE》《王者荣耀》《胜利女神：NIKKE》等爆款游戏的发行商，也是《沙丘：觉醒》（Funcom 开发）、《战锤40K：Darktide》等众多游戏的深度合作伙伴。欲了解更多关于 Level Infinite 的信息，请访问 www.levelinfinite.com 。联系信息Kirsty EndfieldSwipe Right PRtencent@swiperight.gg来源: Level Infinite Copyright 2025 亚太商讯 via SeaPRwire.com.

A bubbly boost to Malaysians’ favourite drinks, uniting the nation through flavour and funKUALA LUMPUR, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - This Merdeka and Hari Malaysia, Spritzer Sparkling is adding an extra pop to the nation’s celebrations with “Kasi Sparkling, Baru Kick!”. This high-energy campaign is a tribute to Malaysia’s favourite pastime – bonding over hearty food and thirst-quenching drinks. From the eternal “Where to eat?” debates to late-night mamak sessions that stretch into early mornings, these shared moments are part of what makes us Malaysian.Inspired by the lively, welcoming atmosphere of mamak restaurants nationwide – the melting pot where Malaysians of every race, language, and background gather – Spritzer Sparkling is bringing a fun twist to your favourite local beverages with exciting engagement games and prizes to be won at selected mamak outlets, guaranteed to refresh your senses and spark national pride.Mamak Culture, Now with More SparkleFrom teh ‘o’ to sirap limau and asam boi, Malaysian drinks are iconic in their own right. Spritzer Sparkling is taking these familiar flavours and giving them a bubbly boost at some of your favourite neighbourhood mamak restaurants, creating new taste experiences that blend tradition with modern fun.Mamak restaurants have always been the heart of get-togethers for Malaysians from all walks of life; where friends, families, and even strangers share tables, stories, and laughter. This campaign captures that same magic in every sip, celebrating the diversity of our people while proving that great taste knows no boundaries.Photo 1: The three new Spritzer Sparkling drink recipes in the Kasi Sparkling, Baru Kick! CampaignA Campaign Video That is Bursting with EnergyShowcasing the Malaysian spirit, “Kasi Sparkling, Baru Kick!” is a colourful, feel-good celebration video featuring “Aneh”, the friendly mamak waiter. Infused with a twist on our favourite thirst-quenchers, the campaign highlights three mouth-watering drink recipes, each given an irresistible sparkling twist, brought to life by a vibrant local cast speaking different regional dialects, with Aneh delivering the mamak’s urban rhythm in his signature rap style.Watch it now on Spritzer Water YouTube channel and feel the fizz yourself.Photo 2: Kasi Sparkling, Baru Kick! campaign videoJoin the Festivities NationwideFrom Merdeka to Malaysia Day, the celebration will come alive with a sparkling kick at selected mamak chain outlets – including Restoran Nasi Kandar Subaidah, Restoran Hameediyah, and Nasi Kandar Bestari. Enjoy exclusive combo deals featuring the new sparkling drink creations and join exciting roving roadshows designed to surprise, delight, and refresh your taste buds.Whether you are there for the food, the drinks, or the atmosphere, you will not want to miss this limited-time celebration. All event details, locations, and recipes are available at the official campaign page: sparklingmerdeka2025.spritzer.com.mySo, this season, let us raise our glasses to unity, flavour and fizz. Your favourite local drinks are getting a sparkling new twist—Malaysian flavours with extra kick—ready to enjoy at home or at your favourite mamak. Taste the celebration, anywhere you are.About SpritzerEstablished in 1989, Spritzer is Malaysia’s largest producer of bottled water, offering a wide range of products that include natural mineral water, distilled water, sparkling water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.Our water is sourced from deep underground aquifers within 430 acres of pristine rainforest, naturally protected from pollution. It takes over 15 years to filter through ancient rock layers, becoming enriched with essential minerals, particularly silica, which supports collagen formation for healthy skin and strong bones.Spritzer is committed to sustainability and innovation, using 100% recyclable packaging and working toward becoming a fully circular brand by 2030. Our Industry 4.0 facilities and zero-energy automated warehouse demonstrate our dedication to efficiency, environmental care, and forward-thinking growth.For more information, please visit www.spritzer.com.my.For media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2025 ACN Newswire via SeaPRwire.com.

- 朗豪坊商场开业20周年"立足本地，引领全球潮流文化"，成品牌进驻热点，Chiikawa拉面首间海外分店掀热潮- 花园道三号于2025年到期的租约已全部处理，续约率维持在高水平- 朗豪坊办公楼推出结合六大健康维度"6D Wellness"的创新概念，强化其一站式身心健康及生活时尚总汇的市场定位- 香港银行同业拆息下降节省利息开支，2025年债务成功全额再融资香港，2025年8月20日 - (亚太商讯 via SeaPRwire.com) - 持有花园道三号及朗豪坊物业的冠君产业信托（股份代号：2778）公布截至 2025 年 6 月 30 日止的中期业绩。业绩摘要 2025上半年2024上半年变动租金收益总额 （百万港元）1,0291,115- 7.6%物业收益净额（百万港元）859954- 10.0%可分派收入（百万港元）476544- 12.6% 每基金单位分派（港元）0.07010.0809- 13.3% 于2025年6月30日于2024年12月31日变动物业组合总值（百万港元）58,09860,104- 3.3%每基金单位资产净值（港元）6.797.16- 5.2%资产负债比率24.5%23.7%+ 0.8pp概览2025年上半年，尽管全球经济因贸易紧张局势和地缘政治冲突而面对重重阻力，但香港的市场气氛获多项利好因素支持。股市回暖、香港银行同业拆息于第二季回落，住宅销售趋稳定，以及旅游业稳步复苏均有助抗衡外部压力。然而，港人外游热潮未退，消费力外移令本地零售市道受压。与此同时，写字楼租赁市场依然淡静，反映供求持续失衡。在此市况下，本信托的可分派收入下跌12.6%至4.76亿港元，而每基金单位分派（"每基金单位分派"）则减少13.3%至0.0701港元。冠君产业信托行政总裁侯迅女士（左），冠君产业信托投资及投资者关系总监陆嘉萍女士（右）花园道三号虽然中环整体写字楼市场的租赁动力仍然疲弱，但随着金融市场转趋活跃，我们接到的租赁查询有所增加，需求主要来自金融相关企业。花园道三号落实引进一批新的租赁面积较小的租户，包括家族办公室；而一名现有银行业租户亦于物业内扩充。于2025年6月30日，花园道三号写字楼的出租率为80.7%。该物业的租金收益期内减少5.4%至5.40亿港元（2024年：5.71亿港元）。我们持续推动续租工作，2025年到期的租约已全部处理完毕且续约率维持在高水平，当中包括多名主要租户的续租。而2026年到期的租约亦有超过70%已续租。朗豪坊办公楼报告期内，朗豪坊办公楼推出名为"6D Wellness"的YouTube频道，藉此强化朗豪坊办公楼作为一站式身心健康及生活时尚总汇的市场定位。于2025年6月30日，在该物业的租户组合中，生活时尚（身心健康）行业租户占比达68%。于2025年6月30日，朗豪坊办公楼的出租率保持在86.9%的稳定水平。我们扩大了共享工作空间的营运规模并增设"Social Wellness Hall"，专为举办工作坊及交流活动而设，正好呼应办公楼推广身心健康的定位。市场租金继续面对挑战，租金收益因而减少9.1%至1.51亿港元（2024年：1.66亿港元）。冠君产业信托行政总裁侯迅女士朗豪坊商场今年迎接开业20周年的朗豪坊商场，继续秉持"Stay Local，Trend Global"（"立足本地，引领全球潮流文化"）的愿景。透过沉浸式体验和限定商品，我们成功吸引破纪录的人潮及推动销售，并在八月刷新单日人流纪录。近日，首次进军香港的时装品牌BENLAI，以及全城首家以生活风格为主题的期间限定店Umbro均在朗豪坊商场开业，人气拉面店Chiikawa Ramen Buta亦选址朗豪坊商场设立首家海外分店，旋即成为高人气新热点。于2025年6月30日，商场的出租率维持在99.2%的高水平，目前属已承诺悉数租出的状态。消费行为的改变为租户带来挑战，租金收益跌至3.38亿港元（2024年：3.78亿港元）。分派本信托期内可分派收入下跌12.6% 至4.76亿港元（2024年：5.44亿港元），而每基金单位分派则减少13.3%至0.0701港元（2024年：0.0809港元）。按2025年6月30日的基金单位收市价2.08港元计算，相当于年度分派率6.7%。资产值于2025年6月30 日，本信托旗下物业组合的估值为581亿港元，较2024年12月31日的601亿港元减少3.3%。可持续发展我们继续透过提升气候抗御力、建立有意义的联系及促进社区福祉，为我们的生态圈创造共享价值。报告期内，花园道三号引入人工智能制冷机组优化系统，全年节省大厦制冷设备的能源用量达6.1%。我们透过"绿'惜'环保约章"计划，推动写字楼和零售租户携手实现可量化的环保目标。此外，我们举办以"创新．启发．融合"为主题的"冠君产业信托 ESG Gala"，凝聚逾千名租户和商业伙伴，共同推进可持续营运及共融举措。展望尽管香港零售业已重拾增长，金融市场亦见反弹，预料本信托于2025年后续期间的整体经营环境依然严峻。虽然港元利率回落有助节省利息支出，但续租租金下跌或将持续压抑租金收益及令分派较去年为低。面对竞争激烈的市场环境，我们将继续以灵活的营运策略积极应对。有关冠君产业信托(股份代号：2778)冠君产业信托拥有及投资提供租金收入的写字楼及零售物业。信托主要投资位于优越地点的甲级商用物业。现时拥有花园道三号及朗豪坊两幢位于香港的地标性物业，并以合资股权形式拥有位于伦敦市中心的 66 Shoe Lane，总楼面面积约300万平方呎，让投资者可直接投资于优质甲级写字楼及零售物业。信托自2023年荣获全球房地产GRESB可持续的最高五星级别。冠君产业信托管理人乃鹰君资产管理（冠君）有限公司，为鹰君集团的成员。网站: www.championreit.com Copyright 2025 亚太商讯 via SeaPRwire.com.

BRISBANE, AUS, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Cholrem Pty Ltd, an Australian pharmaceutical research company, has published a landmark study in Cardiology Research and Cardiovascular Medicine, revealing that its proprietary cyclodextrin-based therapy Cavadex reverses atherosclerotic cardiovascular disease (ASCVD), the world's leading cause of death.Angiogram: Plaque Reduced Within 6 WeeksThe peer-reviewed case series demonstrates rapid symptom relief and significant regression of arterial plaque, marking a potential paradigm shift in heart disease treatment. The study followed 20 high-risk patients with advanced angina, with 18 (90%) reporting substantial symptom improvement (P0.0001) compared to expected outcomes. Objective imaging confirmed unprecedented results, including Coronary Artery Calcium (CAC) score reductions (e.g., from 591 to 521) and a 70% coronary artery blockage reduced to 27%. Cavadex, formulated with 2-hydroxypropyl-β-cyclodextrin (HPβCD), stimulates the body's natural vascular repair, offering a faster, more effective approach than existing therapies.The late Professor Laurie G. Howes, a renowned Australian cardiologist and study co-author, called Cavadex "the greatest pharmacological development in cardiology since statins." U.S. cardiologist Dr. James C. Roberts, who has treated hundreds with the therapy, noted, "We're seeing rapid, profound improvements in high-risk patients, with objective plaque regression and an excellent safety profile, leveraging a TGA- and FDA-approved molecule."Cholrem, founded by Kyle Hodgetts - a heart disease patient who pioneered Cavadex after conventional treatments failed - has supplied over 20,000 units globally. Despite HPβCD's non-patentable status limiting industry investment, Cholrem is driving this breakthrough forward. The company urges global medical communities to launch large-scale trials to validate these findings for millions suffering from heart disease.About Cholrem Pty Ltd: Cholrem is dedicated to advancing cyclodextrin-based therapies to combat ASCVD, the world's top killer, with a mission to deliver innovative, life-saving treatments. Cardiology Research and Cardiovascular Medicine Published Paper: https://www.gavinpublishers.com/article/view/cyclodextrin-therapy-for-atherosclerotic-cardiovascular-disease-a-case-series-on-plaque-regression-and-symptomatic-improvementRelated Videohttps://www.youtube.com/watch?v=5JqIanZxmuQContact InformationKyle HodgettsCholrem Pty Ltd Founder & CEOinfo@cholrem.com+61 424830574Related Videohttps://www.youtube.com/watch?v=5JqIanZxmuQSOURCE: Cholrem Pty Ltd Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial Highlights:(RMB Million)For the Six Months Ended 30 June1H 20251H 2024% ChangeRevenue5,8506,007- 2.61%Gross Profit8481,003- 15.45%Profit Before Tax839899-6.67%Net Profit Attributable to Owners of the Company641687- 6.70%Basic Earnings per Share (RMB)0.140.15- 6.67%HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - China BlueChemical Ltd. (“China BlueChem” or the “Company,” stock code: 3983), China’s largest chemical fertilizer central enterprise in both production capacity and production volume, has announced its unaudited interim results for the six months ended 30 June 2025. In the first half of 2025, the Company realized a revenue of RMB 5.85 billion, slightly down by 2.6% year-on-yearly. Net profit attributable to owners of the Company amounted to RMB 641 million, a slight year-on-year decrease of 6.7%.Mr. RAO Shicai, CEO of China BlueChem said, “Despite the complex and volatile external environment and internal structural adjustment pressures, the Company’s key operating indicators have been successfully achieved. During the period, the Company has strengthened its safety production management, actively expanded its market and sales channels, and further developed lean management, while at the same time steadily implementing various measures to stabilize growth, reinforce reforms, and enhance efficiency Moreover, the Company has consistently adhered to a philosophy of green and sustainable development. Its methanol plant has been awarded the honorary title of “Energy Efficiency Leader” by the China Petroleum and Chemical Industry Federation for 14 consecutive years, and its synthetic ammonia plant has been awarded the honorary title of “Water Efficiency Leader” by the China Nitrogen Fertilizer Industry Association for 6 consecutive years. It also won the “2025 ESG Model Enterprise Award” at the 4th International Green Zero-Carbon Festival and ESG Leadership Summit, setting a benchmark for sustainable development brands.”In respect of production management, the Company continuously strengthened production and operation control and system management, thoroughly implementing the concept of green development and stable safety production conditions. During the period, methanol production at CNOOC Fudao and the cumulative throughput at Basuo Port both reached new highs for corresponding periods in history. The CNOOC Huahe Chemical Fertilizer Plant achieved 314 days of continuous operation, making a new record of itself and setting outstanding production indicators. In the first half of the year, the Company produced 968,000 tonnes of urea, 781,000 tonnes of methanol, 450,000 tonnes of phosphate fertilisers and compound fertilizers, and 132,000 tonnes of acrylonitrile series products.With regard to sales management, amidst the complex and ever-changing market situation, the Company has continued to further strengthen market analysis and keep up with the market to implementprecise pricing. By solidifying the weekly production and sales coordination meeting mechanism, the Company has optimised storage and transportation coordination, and ensured efficient product circulation., It has also comprehensively advanced market expansion and efficiency improvements. In the first half of the year, the Company sold 996,000 tonnes of urea, 726,000 tonnes of methanol; 386,000 tonnes of phosphate fertilizers and compound fertilizers, and 127,000 tonnes of acrylonitrile series products.As for green development, the Company accelerated the implementation of key projects, successfully producing the first tonne of green methanol in China using urban waste as raw material, and obtaining International Sustainability and Carbon Certification (ISCC) in the first half of the year. The green methanol has been successfully applied to domestically produced dual-fuel vessels, marking the first domestic use of green methanol. Furthermore, the Company achieved unified integration of monitoring data into the environmental protection information system, with pollutant emissions meeting standards at 100% for three consecutive years, and the number of environmental pollution incidents remaining at zero. The comprehensive utilization rate of phosphogypsum at DYK increased from 61.15% to 73.09%, exceeding the target requirements.Looking ahead to the second half of the year, urea will remain in a capacity expansion cycle and the overall market will continue to be oversupplied. In the third quarter, demand will be stronger driven by the combined impact of the export window and agricultural demand. Entering the fourth quarter, the release of new capacity and weakening demand will create a ripple effect, and prices are expected to remain under pressure. The prices of monoammonium phosphate may fluctuate within a narrow range at a high level, supported by strong raw material costs and favorable demand factors. The diammonium phosphate market is expected to maintain a stable consolidation cycle. In the third quarter, domestic autumn storage and export demand will resonate, resulting in strong overall demand and stable prices. In the fourth quarter, the demand for phosphate fertilizer is expected to decline overall, putting downward pressure on prices, but overall fluctuations will be relatively limited, supported by cost factors. In the second half of the year, the trend of methanol supply is expected to remain accommodative. Benefited from anti-involution in mainland China and the restriction policy on new coal-to-methanol projects, the supply and demand structure is expected to be improved. Downstream demand may see a phased recovery, with the overall market trend characterized by fluctuations. Regarding acrylonitrile, the oversupply situation will further intensify. Any improvement in acrylonitrile prices will require major domestic companies to reduce plant loads.Mr. RAO Shicai, CEO of China BlueChem said, “In the second half of 2025, the Company will refine its equipment management system to ensure safe and stable operation of facilities and establish a solid foundation for intrinsic safety. At the same time, it will focus on establishing its quality positioning, expanding market and sales, and enhancing marketing effectiveness. "AI+" initiatives will be promoted across the Company to accelerate the deep integration of digital technology and the real economy. In addition, the Company will push forward the study of key projects on the utilization of carbon-rich natural gas and strengthen communication matrix management to continuously enhance brand value.”About China BlueChemical Ltd.China BlueChemical Ltd. (“China BlueChem”) is a listed company that specialises in the development, production and sales of chemical fertilisers and synthetic chemical products. It is the largest Central enterprise in the field of chemical fertilisers in terms of both production capacity and production volume. The Company is a subsidiary of China National Offshore Oil Corporation which mainly engages in the exploration, development, production and sales of crude oil and natural gas. On 29 September 2006, China BlueChem was listed on the main board of The Stock Exchange of Hong Kong Limited with the stock code 3983. Currently, its production facilities are located in Hainan, Hubei and Heilongjiang, China, with a total designed annual production capacity of 1.84 million tonnes of urea, 1.3 million tonnes of phosphate and compound fertilisers (mono-ammonium phosphate, di-ammonium phosphate and compound fertiliser), 1.4 million tonnes of methanol, 200 thousand tonnes of acrylonitrile and 70 thousand tonnes MMA. It has a deep water port with a designed annual throughout capacity of 18.28 million tonnes in Dongfang city, Hainan province. Boasting continued growth of its brand value, the Company’s brand value reached historical high at RMB7.258 billion in 2025. Besides, the Company was awarded “ËSG Model Enterprise 2025” at the 4th International Green Zero-Carbon Festival Cum ESG Leaders Conference.For more information about the Company, please visit its website:www.chinabluechem.com.cn. Copyright 2025 ACN Newswire via SeaPRwire.com.

- Langham Place Mall marks 20 years of excellence "Stay Local, Trend Global", becoming a brand hotspot with Chiikawa Ramen Buta’s premier overseas debut- Three Garden Road successfully concluded all 2025 expirations with high retention rate- Langham Place Office Tower unveiled “6D Wellness” concept, an innovative concept strengthening its positioning as a one-stop wellness and lifestyle hub- Lower Hibor reduced interest expenses; all 2025 debt successfully refinancedHONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - Champion Real Estate Investment Trust (stock code: 2778), the owner of Three Garden Road and Langham Place, announces its financial results for the six months ended 30 June 2025.Summary of financial results 1H 20251H 2024ChangeTotal Rental Income (HK$ million)1,0291,115- 7.6%Net Property Income (HK$ million)859954- 10.0%Distributable Income (HK$ million)476544- 12.6% Distribution per unit (HK$)0.07010.0809- 13.3% 30 Jun 202531 Dec 2024ChangeGross Value of Portfolio (HK$ million)58,09860,104- 3.3%Net Asset Value per unit (HK$)6.797.16- 5.2%Gearing Ratio24.5%23.7%+ 0.8ppOverviewWhile the global economy faced headwinds from trade tensions and geopolitical conflicts in the first half of 2025, Hong Kong’s market sentiment found support from several positive developments. A stock market revival, declining Hong Kong Interbank Offered Rates (“Hibor”) in the second quarter, stabilised residential sales and a steady tourism rebound helped counterbalance external pressures. However, persistent outbound travel by residents continued to divert spending elsewhere, weighing on local retail sales. Meanwhile, the office leasing market remained subdued, reflecting an ongoing imbalance between supply and demand. Against this backdrop, distributable income of the Trust decreased by 12.6% to HK$476 million and distribution per unit (“DPU”) declined by 13.3% to HK$0.0701.Ms. Christina Hau, Chief Executive Officer of Champion REIT (Left), Ms. Amy Luk, Investment and Investor Relations Director of Champion REIT (Right)Three Garden RoadAlthough overall office leasing momentum in Central remained suppressed, we received increased leasing inquiries amid rising financial market activities, with demand primarily from finance-related firms. Several new small-sized tenants, including family offices, committed to establishing operations in the property, while an existing banking sector tenant expanded its presence here. Occupancy of Three Garden Road office was 80.7% as at 30 June 2025. Rental income of the property fell 5.4% to HK$540 million (2024: HK$571 million). We advanced lease renewal efforts, successfully concluding all 2025 expirations with a high retention rate, including several anchor tenant renewals. For 2026, over 70% of the expiring leases have already been renewed.Langham Place Office TowerDuring the reporting period, Langham Place Office Tower launched “6D Wellness” YouTube channel to strengthen the property’s positioning as a one-stop wellness and lifestyle hub. As at 30 June 2025, lifestyle (wellness) tenants comprised 68% of the property’s tenant mix. Occupancy of Langham Place Office Tower remained stable at 86.9% as at 30 June 2025. The expanded co-working space introduced a Social Wellness Hall for wellness workshops and events, resonating with the property’s wellness positioning. Market rental continued to face challenges with rental income dropped by 9.1% to HK$151 million (2024: HK$166 million).Ms. Christina Hau, Chief Executive Officer of Champion REITLangham Place MallAs Langham Place Mall celebrates its 20th anniversary in 2025, it continues to embrace its bold “Stay Local, Trend Global” vision. Through immersive experiences and exclusive merchandise, we successfully attracted record crowds and drove sales, establishing new single-day footfall record in August. Recently, fashion brand BENLAI, marking its inaugural Hong Kong flagship presence in the mall, and Umbro’s first in town lifestyle themed pop-up store, have commenced operations. Further elevating the mall’s offerings, Chiikawa Ramen Buta has chosen this location for its premier overseas outlet, shortly becoming a hotspot since opening. Occupancy of Langham Place Mall remained high at 99.2% as at 30 June 2025, reaching full committed occupancy currently. Since changing consumer behaviour has posed challenges for tenants, rental income of the mall declined to HK$338 million (2024: HK$378 million).DistributionDistributable income of the Trust decreased by 12.6% to HK$476 million (2024: HK$544 million) and DPU declined by 13.3% to HK$0.0701 (2024: HK$0.0809). Based on the closing unit price of HK$2.08 recorded as at 30 June 2025, the total DPU represented an annualised distribution yield of 6.7%.Asset ValueThe appraised value of the Trust’s property portfolio was HK$58.1 billion as at 30 June 2025, declining by 3.3% from HK$60.1 billion as at 31 December 2024.SustainabilityWe continue to create shared values across our ecosystem through initiatives that drive climate resilience, build meaningful connections, and support community wellness. During the reporting period, we implemented an AI-powered chiller optimisation system at Three Garden Road, achieving 6.1% annual energy savings. Through our EcoChampion Pledge programme, we bring both office and retail tenants together in the shared commitment to fulfilling measurable environmental goals. Furthermore, Our Champion REIT ESG Gala, themed "Innovation - Inspiration · Integration", brought together over 1,000 tenants and business partners to advance sustainable operations and inclusive practices.OutlookAlthough Hong Kong retail sector has returned to growth and the financial market has rebounded, the overall operating environment of the Trust is expected to remain challenging in the rest of 2025. While lower HKD interest rates should reduce interest expenses, negative rental reversion will likely continue to suppress rental income and reduce distributions compared to last year. We remain committed to maintaining operational agility to navigate this competitive market landscape.About Champion REIT (stock code: 2778)Champion Real Estate Investment Trust is a trust formed to own and invest in income- producing office and retail properties. The Trust focuses on Grade A commercial properties in prime locations. It currently offers investors direct exposure to nearly 3 million sq. ft. of prime office and retail floor area. These include two Hong Kong landmark properties, Three Garden Road and Langham Place, as well as a joint venture stake in 66 Shoe Lane in Central London. The Trust has been awarded the top five-star rating by GRESB since 2023. Champion REIT is managed by Eagle Asset Management (CP) Limited, a member of the Great Eagle Group.Website: www.championreit.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - uSMART Securities, a strategic investment of Chow Tai Fook (Holding) Limited, is pleased to announce the official launch of its new branches at Hong Kong’s Lok Ma Chau MTR Station and West Kowloon High-Speed Rail Station, strategically positioned to serve cross-border clients and passengers. A grand opening ceremony was held at the West Kowloon branch, attended by prominent financial professionals.At the event, Mr. Neo Lee, Executive Director of uSMART Securities, stated: "To provide more accessible financial services, uSMART Group plans to open 12 service centers across Hong Kong and Singapore this year, covering key districts such as Tsim Sha Tsui, Causeway Bay, Tsuen Wan, Sheung Shui, and Sheung Wan. This expansion will enhance our regional service network and bring us closer to our local clients."“As a No.1 Hong Kong Funded Fintech Brokerage^ with over 800,000 users globally, uSMART Securities is committed to elevating the investment experience. Our new branches offer comprehensive services, including investment consultations, account opening assistance, and personalized support for seniors and beginners to navigate our trading app," added Neo Lee.(From left to right: Business Development Director of uSMART Securities, Marketing Director of uSMART Securities, Executive Director of uSMART Securities, Head of Research and Asset Management of uSMART Securities and Business Development Manager of uSMART Securities)During the launch period, clients can enjoy exclusive mystery gift upon check in new shop, along with complimentary beverages, and mobile charging services. New customers who open an account at the branch will receive additional rewards. To further penetrate the Hong Kong market, uSMART Securities has introduced its "Trader Account", offering lifetime 0 commission for US and HK Stocks, plus 0 commission for US options trading for local clients.As a token of appreciation, uSMART Securities is rolling out a suite of 0 fee promotions for both new and existing clients, including:1)0% margin interest for IPO subscriptions | 0 handling fees for cash subscriptions2)0 commission & 0 platform fees for 100+ Hong Kong ETFs (covering high-dividend, virtual asset, and index ETFs)3)$0 cost to invest in US & HK stocks Monthly Investment Plan (no commission, platform fee, custody fee, and dividend collection fee)These offers are designed to support investors with different short, medium, and long-term investment strategies, ensuring all uSMART Securities clients could enjoy.Neo Lee also revealed that uSMART Group is actively expanding its teams in Hong Kong and Singapore to strengthen competitiveness. The Group’s newly established Manhattan office in New York will focus on serving hedge funds, family offices, and pre-IPO companies with institutional brokerage, asset allocation, and investment banking advisory services, reinforcing its leadership in fintech brokerage.Moving forward, uSMART Securities remains dedicated to customer-centric innovation, delivering premium offline services and cutting-edge financial solutions for global investors.^”No.1 Hong Kong Funded Fintech Brokerage" is based on TradeGo Cloud data, with uSMART Securities ranking first in monthly transaction volume among local Hong Kong-funded internet brokers for over a year as of May 2025.Terms and conditions apply.About uSMART:Strategic investments from Chow Tai Fook (Holding) Limited, uSMART Securities is a leading Hong Kong Funded Fintech Brokerage founded in 2018. Over the past seven years, it has pioneered the fusion of technology and finance, offering stocks trading, asset management, and wealth management solutions. Its proprietary platforms, uSMART HK APP and uSMART SG APP, operated by uSMART Securities (Hong Kong) and uSMART Securities (Singapore) respectively. It supports investments in Hong Kong stocks, US stocks, A-shares (Shanghai,Shenzhen,and Hong Kong stock connect), Singapore Stocks, Japan Stocks, UK Stocks, US options, ETFs, Funds, Bonds, Asset Management, Structured Notes, Futures, Crypto, Precious Metals, Gold, and forex. Furthermore, uSMART is equipped with a highly professional research and asset management team that offers asset management, wealth management, securities brokerage, institutional business, LPF services, and investment banking, dedicated to serving ultra-high-net-worth individuals and families, corporations, investment institutions, fund companies, and other brokerage firms with comprehensive asset management solutions.For details please visit: https://hk.usmartglobal.com/For any media queries, please contact:Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月19日 - (亚太商讯 via SeaPRwire.com) - 由周大福控股战略入股的uSMART盈立证券欣然宣布香港落马洲港铁站，西九龙高铁站分行已正式投入服务，涵盖陆路出入境和高铁枢纽客戶群。为庆祝这一里程碑，盈立证券今日在西九龙分行举行简单而隆重的开幕仪式，并邀得不少财经界精英出席，令活动生色不少。开幕礼上，盈立证券执行董事李建翰先生（Neo Lee）表示：「为提供更便捷的金融服务方便区内居民，盈立集团计划年内于香港及新加坡两地社区内开设分行，连同总部客户专区，服务点增至12个，进驻尖沙咀，铜锣湾，荃湾，上水及上环等核心地区，全面强化区域服务网络，拉近与本地客户的距离，提供更贴心的服务。」「作为港资科技券商No.1^，全球超过800,000用户，盈立证券十分重视提升用户的投资体验，本次开立分行不但提供综合服务，包括投资咨询，办理开户等，还协助长者及初学者处理开户流程，学习App使用方法等，借此深化本地市场，满足客户对相关服务的殷切需求。」Neo Lee续说。(左起︰盈立证券业务拓展总监邓永麟先生、盈立证券香港市场部总监黄晓霖小姐、盈立证券执行董事兼机构业务负责人李建翰先生、盈立证券资产管理兼投研部总监蒋雄先生及盈立证券业务拓展经理林向尊先生)新开张时间内，前往分行打卡即可获赠神秘礼品1份，同时亦可免费享用饮料及手机充电服务，于分行开户更可额外获得丰富礼品。为进一步开拓香港市场，盈立证券推出「Trader账户」，香港本地客户专享美港股一世免佣，美股期权0佣优惠。为感谢客户的支持，uSMART盈立证券亦同时提供多项真全免优惠，不论新客户或现有客户，均可享受，绝无取巧，优惠包括：1)IPO融资认购0息│现金认购0手续费；2)>100只港股ETF 0佣0平台费（当中包括近期投资者热爱的高息股ETF，虛擬資產相關ETF及指数ETF等）；3)月供美港股0佣0平台费0存管费及免代收股息税以上优惠旨在满足短线，中线及长线投资策略，让持有uSMART盈立证券账户的客户均能受惠。Neo Lee在开幕礼上透露，集团正积极增聘人手，扩充香港及新加坡团队，以支持及推进业务发展，提高本地市场竞争力；而集团旗下的美国办公室亦正式进驻至世界金融中心-纽约曼哈顿城中心，并将专注于对接对冲基金，家族办公室及拟赴美上市企业，提供机构经纪、资产配置及投行咨询等专业服务，巩固全球金融科技券商领域的领先地位。展望未来，uSMART盈立证券秉持以客为本的理念，为更多本地投资者提供星级投资体验及优质线下服务，同时亦致力推动金融服务的创新与升级，为全球客户创造更多价值。^"港资科技券商No.1"是取自捷利金融云截至2025年5月为止连续超过一年数据，uSMART盈立证券为香港本地港资互联网券商月成交总额排行第1。优惠受条件及细则约束关于uSMART盈立证券：由周大福控股战略入股的盈立证券是一间领先科技港资券商，成立于2018年，7年来凭借卓越的战略规划和创新能力，致力于将科技与金融深度融合，业务范围涵盖证券，资产管理，财富管理等领域，为全球投资者独家研发了金融证券交易平台uSMART HK APP和uSMART SG APP，分别由盈立证券（香港）和盈立证券（新加坡）提供服务。集团APP支持港股，美股，A股（沪深港通），新加坡股票，日本股票，英国股票，美股期权，ETF，基金，债券，资管，结构化票据，期货，加密货币，贵金属，黄金和外汇等多元化的投资交易服务，此外更为超高净值个人与家族，企业提供度身订制服务，打造全方位综合性资产管理解决方案。详情可浏览 https://hk.usmartglobal.com/传媒查询：黄晓霖Carrie Wong9788 4665carriewong@usmart.hk Copyright 2025 亚太商讯 via SeaPRwire.com.

深圳，2025年8月19日 - (亚太商讯 via SeaPRwire.com) - 8月18日，康哲药业发布2025年中期业绩，公司营收和利润同比均实现增长，战略转型成效初显。报告期内，公司实现营业收入约40.0亿元（人民币，下同），同比增长10.8%。若全按药品销售收入计算则营收约46.7亿元，同比增长8.9%。实现净利润约9.3亿元，同比增长3.1%。具体来看，康哲药业已走出国采阴霾，业绩将回归持续上升轨道。公司主要非国采独家/品牌产品及创新产品全按药品销售收入合计约29.0亿元，同比增长20.6%，占总收入比重升至62.1%。公司独家/品牌产品、创新产品竞争格局良好、增长可预期性强，目前已成为拉动业绩向上的主力军。根据业绩公告，公司自2018年起擘画"新康哲"转型蓝图，以"产品创新、商业革新、国际拓展"三大战略为支柱，构建可持续的第二增长曲线。行至2025年上半年，良好的经营业绩及创新成果持续落地，证实战略升级已逐步兑现为硬核战果。"新产品"战略推动创新价值兑现 夯实增长后劲立于公司三大战略之首的"产品创新"战略，依托"海外授权+国内合作+自主研发"三维创新机制，持续注入高价值短、中、长期管线，成为驱动增长的重要引擎。目前，创新战略已进入持续收获期，新产品正不断释放商业与临床价值。截至目前，公司已有5款创新药成功于中国实现商业化；2025年内，芦可替尼乳膏和德昔度司他片两款创新产品亦有望获批上市。芦可替尼乳膏是美国FDA以及欧洲EMA批准的首个、也是唯一一个局部JAK抑制剂非节段型白癜风复色产品，有望成为中国获批上市的首款白癜风治疗药物，将填补市场空白，为中国白癜风患者带来新希望。此外，阿尔茨海默病新药ZUNVEYL的中国上市申请(NDA)亦已于今年7月获受理；消费医疗产品注射用聚左旋乳酸微球填充剂已获得上市批准，进一步丰富公司多元化产品矩阵。在研创新管线中，已有多款重磅候选药物进入中国后期临床开发阶段，预计将在未来1-3年内陆续进入商业化，形成持续放量的新动力。其中，合作产品注射用Y-3已完成中国III期临床，该产品为原创单分子1类新药，亦为全球唯一进入临床研究的非肽类PSD95/nNOS解偶联剂，并有望成为首个治疗缺血性卒中并预防卒中后抑郁焦虑的双功能脑细胞保护药物。另一个口服小分子1类新药ABP-671（URAT1抑制剂）用于治疗痛风及高尿酸血症，目前其中国IIb/III期临床正有序推进中。相较现有主流药物，该产品有潜力以更低剂量将尿酸降低至更低水平，并具有溶解痛风石的能力，有望为患者提供疗效更优、安全性更高的治疗选择。康哲药业亦持续增厚创新储备，不断夯实全链条创新实力，以实现创新产品分阶段、源源不断获批上市。2025上半年，公司新增ZUNVEYL、MG-K10（长效抗IL-4Rα人源化单抗注射液）两款合作开发创新产品。截至目前，公司累计布局约40款差异化创新管线，其中约20项为自主研发项目。同步推进"新模式"、"新地域"战略 拓展多维增量空间根据业绩公告，康哲药业持续推进"新模式-商业革新"战略，以多元生态锻造抗周期韧性；并坚定执行"新地域-国际拓展"战略，以产业国际化出海模式构建多维增长格局。在商业革新战略下，公司持续聚焦专科领域，同时拓展新零售、新媒体渠道，构建"院内+院外"、"线上+线下"全覆盖的营销推广体系，并持续强化消费医疗产品布局。公司皮肤健康业务"德镁医药"已在这一具消费属性的赛道崭露头角，自2021年独立运营以来，已实现皮肤疾病领域适应症覆盖广度、皮肤处方药收入规模的双重领先，将通过介绍上市、实物分派方式，拟分拆于香港联交所主板独立上市，进一步释放其独立价值与高成长潜力。国际化方面，2025年7月15日，公司以介绍方式成功于新加坡交易所完成第二上市，"产业国际化"战略迈入新里程。以新加坡为枢纽，公司构建起覆盖"研-产-销"的新兴市场全链条业务体系。截至目前，商业化平台公司Rxilient已在东南亚、中东、港澳台等地区累计提交近20款药品和器械注册申请，涵盖皮肤科、眼科、肿瘤、自免、中枢神经等领域。芦可替尼乳膏（白癜风适应症）已在澳门、香港获批，并已递交新加坡、台湾注册申请；静脉注射用特瑞普利单抗（首个被中国NMPA及美国FDA批准上市的国产抗PD-1单抗药物）已提交马来西亚等五国注册申请；替瑞奇珠单抗注射液、蔗糖羟基氧化铁咀嚼片亦在香港获批。同时，公司持股45.0%的联营CDMO生产工厂PharmaGend，目前已具备片剂、胶囊等口服固体制剂年产10亿片的能力，并获得新加坡HSA颁发的生产许可证、美国FDA cGMP认证及瑞士QP审计通过。PharmaGend鼻喷剂、乳膏、注射剂等新产线的建设正稳步推进中，为国际市场提供高标准生产交付能力。展望未来，"新康哲"增长逻辑有望加速兑现，盈利能力与业绩韧性将同步提升。公司正构建以差异化创新为核心、多元生态协同驱动、国际化布局支撑的增长体系，为高质量发展打开长期空间，为全球患者提供高品质医药产品和服务，为股东带来可持续回报。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，其中皮肤健康业务已成为该细分领域的龙头企业，带来专科规模效率。同时，康哲药业持续深化东南亚及中东区域业务发展，助力高质量持续健康发展。康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com.

财务摘要(人民币亿元)截至 6 月 30日止年度2025年中期2024年中期变动收入58.5060.07- 2.61%毛利8.4810.03- 15.45%税前利润8.398.99-6.67%本公司拥有人应占净利润6.416.87- 6.70%每股基本盈利 (人民币元)0.140.15- 6.67%香港，2025年8月19日 - (亚太商讯 via SeaPRwire.com) - 中海石油化学股份有限公司(「中海石油化学」或「公司」，股份编号：3983) 公布截至2025年6月30日止日止半年度未经审计之业绩。2025年上半年公司实现收入人民币5,850百万元，同比微跌2.6%，本公司拥有人权益应占净利润为人民币641百万元，同比微跌6.7%。中海石油化学首席执行官饶仕才先生表示：「纵使面对外部环境复杂多变与内部结构调整压力，公司主要经营指标仍然完成良好。期内，公司继续强化安全生产管理，积极拓展市场与销售渠道，深化精益管理；同时，扎实推进稳增长、深改革、提效能各项工作。此外，公司坚持秉持绿色可持续发展理念，甲醇装置连续十四年获评石化联合会『能效领跑者』荣誉称号，合成氨装置连续六年蝉联氮肥协会『水效领跑者』 荣誉称号，并荣膺第四届国际绿色零碳节暨ESG领袖峰会『2025 ESG 典范企业奖』，树立了可持续发展品牌标杆。」生产管理方面，公司持续强化生产经营管控与体系管理，深入践行绿色发展理念，安全生产形势总体平稳。期内，海南富岛甲醇产量与八所港累计吞吐量均创历史同期新高，华鹤煤化工化肥装置实现314天长周期运行，刷新自身纪录，生产指标表现亮眼。上半年，公司生产尿素96.8万吨、甲醇78.1万吨、磷肥及复合肥45.0万吨、丙烯腈系列产品13.2万吨。销售管理方面，面对复杂多变的市场形势，公司持续深化市场研判，紧贴市场精准定价。通过固化产销协同周例会机制，优化储运衔接，保障产品高效流通。同时加大出口创效力度，全面推进拓市增效。上半年，公司销售尿素99.6万吨、甲醇72.6万吨、磷肥及复合肥38.6万吨、丙烯腈系列产品12.7万吨。绿色发展方面，上半年公司加速推进重点项目落地，成功产出以城市垃圾为原料的国内首吨绿色甲醇，并获得国际可持续发展和碳认证（ISCC）。该产品成功应用于国产双燃料船舶，实现了国内绿色甲醇首次加注。此外，公司实现监测数据统一接入环保资讯系统，污染物排放连续三年100%达标，环保污染事故事件保持为零。其中，大峪口化工磷石膏综合利用率由61.15%提升至73.09%，超额完成指标要求。展望2025下半年，尿素仍处于产能扩张周期，市场整体将延续「供大于求」格局，三季度受出口窗口期与农需支撑迭加影响，需求较强;进入四季度后，新增产能释放与需求转淡形成共振，价格预计持续承压。磷酸一铵价格或呈高位窄幅震荡态势，一方面原料成本支撑强劲，另一方面需求端亦有利好因素加持。磷酸二铵市场预计维持稳中整理节奏，三季度国内秋储与出口需求共振，整体需求旺盛，价格将保持平稳运行;四季度磷肥需求预计整体回落，价格存在回调压力，但受成本端支撑，整体波动幅度将较为有限。预计下半年，甲醇供应延续宽松态势，受益于国内反内卷及煤制甲醇新建项目政策限制，供需结构有望改善，下游需求或呈阶段性回暖，市场整体走势以震荡为主。丙烯腈方面，供过于求的格局预计将进一步加剧，丙烯腈价格若要出现好转，需依赖国内主流企业降低装置负荷。公司首席执行官饶仕才先生表示：「2025年下半年，公司将聚焦完善设备管理体系，保障装置安全平稳运行，夯实本质安全基础；同时着力打造品质定位，抓好拓市拓销，提升营销创效能力。此外，公司将推进『人工智慧+』行动，加速数智技术与实体经济的深度融合，推动富碳天然气利用重点项目研究及强化传播矩阵管理，持续提升品牌价值。」有关中海石油化学股份有限公司中海石油化学股份有限公司(「中海石油化学」)是专门从事化肥及相关化工产品开发、生产及销售的上市企业，是化肥产能及产量最大的中央企业，为从事石油和天然气勘探、开发、生产及销售的中国海洋石油集团有限公司之子公司。中海石油化学于2006年9月29日在香港联合交易所主板挂牌上市，股份编号：3983。公司现有生产设施位于中国海南、湖北及黑龙江，总设计年产能达184万吨尿素、130万吨磷复肥(磷酸一铵、磷酸二铵和复合肥)、140万吨甲醇、20万吨丙烯腈及7万吨MMA，公司并拥有位于海南省东方市的设计年吞吐能力为1,828万吨的深水港口。中海石油化学的企业品牌价值持续提升，2025年达72.58亿元，创历史新高。2025年，中海石油化学荣膺第四届国际绿色零碳节暨ESG领袖峰会『2025 ESG 典范企业奖』。如欲查询更多公司资料，请浏览公司网站 www.chinabluechem.com.cn。 Copyright 2025 亚太商讯 via SeaPRwire.com.

SHENZHEN, CHINA, Aug 19, 2025 - (ACN Newswire via SeaPRwire.com) - On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year.The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth.According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements.“New Products” Strategy Drives Innovation Value Realization and Solidifies Growth MomentumAt the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value.To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio.Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth.Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option.CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects.Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional GrowthAccording to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets - International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model.Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential.In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market.Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.

Susan Rohac, ICD.D, built one of Canada's largest and most active climate funds, overseeing a Pan-Canadian team of investment professionals and managed a portfolio over $1 billion in assets.Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 18, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the appointment of Mrs. Susan Rohac, ICD.D, to its Board of Directors, effective immediately. Mrs. Rohac replaces long-serving director Robin Dow, who has stepped down from the Board to focus on personal pursuits and other interests, and will continue to support a smooth transition.Susan Rohac had an extensive thirty-four (34) plus year career at the Business Development Bank of Canada ("BDC"), holding various leadership roles. Her final role was as Managing Partner of the Climate Tech venture capital fund, which she held from 2017 to May 2025. In this role, she oversaw a pan-Canadian team of investment professionals and managed a portfolio of over $1 billion in assets. This portfolio included a fully deployed $600 million fund I and a $500 million fund II launched in 2022 that focused on investing in Canada's most promising clean technology companies. Susan has invested in a diverse range of climate technologies across various sectors, including energy, mobility, built environment, carbon management, and industry & resource space, including advanced materials and critical minerals. In 2024, Susan was recognized as a Climate Leader by the Clean50 and received the Clean16 award. She holds undergraduate degrees in both science and finance and an executive MBA from the University of Ottawa. In 2024, she also obtained her ICD.D governance designation from the University of Toronto. Passionate about the environment and climate technologies, Susan currently sits on several governance and advisory boards and is actively involved with a few organizations that are aligned with her interests."We are delighted to welcome Susan to our Board," said Jeff York, Founder and Chairman of Focus Graphite. "She brings a strong track record in corporate finance and scaling industrial technologies, with a deep appreciation for Canada's critical minerals opportunity. Her experience and connections in the industry will be invaluable.""I am honored to join Focus Graphite at such an important moment," said Ms. Rohac. "The shift to green energy is driving unprecedented demand for secure supplies of critical minerals, and Canada has an opportunity to lead in building a reliable, sustainable graphite supply chain here at home. Beyond batteries, graphite is essential for advanced manufacturing and defense applications that underpin national security. I look forward to working with the team to help strengthen North America's self-sufficiency and reduce reliance on foreign supply."Mr. York added, "On behalf of the company and our shareholders, I want to thank Robin for his years of service and leadership. His guidance helped position Focus for its next phase of growth."Focus Graphite is also pleased to announce its participation in the Canadian Critical Minerals Investment Forum, an international trade mission organized by Natural Resources Canada and Invest in Canada. The event will be held in Tokyo, Japan from August 26-28, 2025, and in Korea from August 29-30, 2025. Focus Graphite is one of only two Canadian graphite companies attending the Forum, which brings together global investors, government officials, and industry leaders to advance critical minerals partnerships. In addition to the Forum, the Company will hold a series of bilateral meetings in both countries to further strategic discussions with potential partners and customers.On August 14th, 2025, Focus Graphite visited its Lac Knife project site near Fermont, Québec. The Company was pleased to host a representative from Korea Mine Rehabilitation and Mineral Resources Corporation ("KOMIR") alongside its newest board member, Susan Rohac. During the visit, Focus also met with officials from the Town of Fermont to provide a corporate and project update, highlighting recent progress and outlining the Company's pathway toward advancing Lac Knife to a fully permitted mining operation.In connection with Ms. Rohac's appointment, the Company has granted her 250,000 stock options pursuant to its Stock Option Plan. The options are exercisable at a price of $0.35 per common share and will expire on August 17, 2030. They are subject to the terms of the Plan as well as the policies of the TSX Venture Exchange.Image 1: Focus Graphite executives, IOS Geosciences, and a representative from KOMIR visit the Lac Knife project near Fermont, Québec, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_001full.jpgImage 2: Focus Graphite executives and IOS Geosciences visit with representatives from the Town of Fermont, QC, August 14, 2025To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/262819_1a756ef144f309ad_002full.jpgAbout Invest in CanadaInvest in Canada is Canada's foreign direct investment (FDI) attraction and promotion agency. We find the best to invest in Canada. This means working with our partners across the country and worldwide to attract global companies and support their expansion plans in Canada.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the advancement of the Lac Knife project through permitting and development activities, the Company's participation in the Canadian Critical Minerals Investment Forum in Japan and Korea and the potential outcomes of related bilateral meetings, the anticipated benefits of Ms. Rohac's appointment to the Board of Directors, the Company's ability to establish strategic partnerships and secure future customers, and its positioning as a near- and long-term supplier of specialty graphite materials within North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262819 Copyright 2025 ACN Newswire via SeaPRwire.com.

Development Highlights- During the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.- As of 30 June 2025, the Group had a total of 37 innovative drug candidates in the field of oncology, 7 innovative drug candidates related to liver/metabolic diseases, 13 innovative drug candidates related to the respiratory, and 6 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 2 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 11 innovative oncology drug candidates, 1 innovative liver/metabolic diseases drug candidate, 3 innovative respiratory system drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. In addition, the Group had a total of 13 biosimilar or generic drug oncology candidates, 6 additional biosimilar or generic liver/metabolic diseases drug candidates, 12 biosimilar or generic respiratory system drug candidates, and 6 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. It has been approved for nine indications, and three other indications are currently in the marketing application stage. In addition, Anlotinib has a number of new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2024, the Group obtained approval for and launched a total of five national category 1 innovative oncology drugs, namely, Yilishu (Efbemalenograstim alfa Injection), Andewei (Benmelstobart Injection), Anboni (Unecritinib Fumarate Capsules), Anluoqing (Envonalkib Citrate Capsules), and Anfangning (Garsorasib Tablets). It also obtained approval for and launched 4 oncology biosimilars, including Anbesi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab Injection), and Paletan (Pertuzumab Injection). The sales volume of these products accelerated rapidly in the first half of 2025, and they have become important contributors to the Group’s revenue growth.- Lanifibranor (pan-PPAR agonist) is an orally available small molecule drug that is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and enrollment of the patients in the global main cohort has been completed. In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE. Lanifibranor is China’s first MASH drug to enter Phase III clinical trials and is expected to fill the gap in China’s MASH market.- Tianqing Suchang (Budesonide Suspension for Inhalation) is China’s first budesonide nebulized generic drug approved for marketing, breaking the long-term monopoly of branded drugs in the domestic market, and offering an effective, safe and economical high-end product for patients with chronic airway inflammation in China. The product has been included in the national VBP. The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the VBP.- Zepolas/Debaian (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. By upgrading the dosage form, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Aug 18, 2025 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2025 (the “Period”).During the Period, the Group recorded revenue of approximately RMB17.57 billion, a year-on-year increase of approximately 10.7%. Profit attributable to owners of the parent from continuing operations as reported was approximately RMB3.39 billion, a year-on-year increase of approximately 140.2%. Earnings per share attributable to owners of the parent were approximately RMB18.82 cents. The significant year-over-year increase in profit attributable to owners of the parent from continuing operations was mainly driven by the notable growth in revenue and significant increase in dividend income and fair value gain on investments during the Period. Underlying profit attributable to owners of the parent (non-HKFRSs measure) was approximately RMB3.09 billion, a YOY increase of approximately 101.1%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB11.1 billion, bank deposits classified as non-current assets of approximately RMB10.1 billion, and wealth management products of approximately RMB9.29 billion in total, and total fund reserves amounting to approximately RMB30.49 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK5 cents per share (1H2024: HK3 cents).Sales: Strong momentum in R&D innovation with volume growth across multiple fieldsAlways placing utmost importance on research and development (“R&D”), the Group has consistently increased investments to enhance R&D quality and efficiency, which has led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. During the Period, sales of oncology drugs increased by 24.9% year-on-year to approximately RMB6.69 billion, accounting for approximately 38.1% of the Group's revenue. Sales of surgical/analgesic medications increased by 20.2% year-on-year to approximately RMB3.11 billion, accounting for approximately 17.7% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. The EGFR/cMet bispecific antibody TQB2922 is about to initiate a Phase III clinical trial for second-line NSCLC, while the EGFR/cMet bispecific antibody ADC TQB6411 is currently enrolling patients for its Phase I trial, with both products progressing at the forefront in China. Also, the Group is deeply invested in the three major subtypes of breast cancer. The CDK2/4/6 inhibitor “Culmerciclib Capsule (TQB3616)” has the potential to become a best-in-class (BIC) therapy for HR+/HER2- breast cancer. The HER2 bispecific ADC TQB2102 demonstrates potentially superior safety compared to DS-8201, with multiple indications being explored simultaneously, including three breast cancer Phase III trials advancing rapidly. Additionally, the Group has systematically targeted key gastrointestinal cancers such as colorectal, gastric, pancreatic, and liver cancers. LM-108 (CCR8 monoclonal antibody) and TQB2868 (PD-1/TGF-β bifunctional fusion protein) are progressing at the fastest pace globally, with current clinical data showing significant potential.In the field of surgery/analgesia, the Group continuously focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. During the Period, the Group drove the sustained rapid sales growth of Zepolas, and the second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. Meanwhile, Putanning, which was approved in May 2025, is expected to become a new growth driver in this field due to its strengths, such as long-acting analgesia and excellent safety.R&D: Fully Committed to Advancing Innovative Product Development with Enhanced R&D InvestmentDuring the reporting period, the Group had two innovative products approved for marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection). In the first half of 2025, the Group’s sales of innovative products reached RMB7.8 billion, a year-on-year increase of 27.2%. In addition to innovative products, the Group had 5 generic drugs approved for marketing by the NMPA. The overall revenue of generic drugs achieved positive growth in the first half of 2025.The Group has always placed the utmost importance on R&D, continuously improving its R&D capabilities and speed. It considers R&D the foundation for its sustainable development and has continuously increased its investment in R&D. For the six months ended 30 June 2025, R&D costs amounted to approximately RMB3,187.56 million, representing approximately 18.1% of the Group’s revenue. Including capitalised R&D expenditure, approximately 95.7% was recognised in the statement of profit or loss.Prospect: Deepening Innovation and Global Expansion to Accelerate the Building of Global Pharmaceutical Innovation CompetitivenessChina’s pharmaceutical industry is currently embracing historic growth opportunities. With the national strategy of innovation-driven development as the guidance, the country’s biopharmaceutical innovation capabilities have witnessed significant enhancement, such that the R&D of innovative drugs has evolved from the positioning of the “passive mover” towards the “paralleled player,” or even the “market leader” on the global stage. Chinese innovative drugs not only gains strong momentum for growth in the domestic market, but also steadily makes their presence internationally, thus being widely recognized and becoming an indispensable impetus in the innovative pharmaceutical industry worldwide. As the industry leader, the Group remains deeply committed to four core therapeutic areas – oncology, liver/metabolic diseases, respiratory diseases, and surgery/analgesia. The Group aims to be a leading global pharmaceutical company through delivering innovative therapies for patients.While being firmly rooted in the Chinese market, the Group is expanding its strategic horizon to embrace global opportunities, and leveraging internationalization to accelerate its innovation and development. In the meantime, the Group is vigorously promoting its global strategic collaboration deployments through diversified approaches of collaborations such as business development (BD), strategic acquisitions, etc. In July 2025, the Group announced the full acquisition of LaNova Medicines. LaNova Medicines boasts world-leading antibody discovery and ADC technology platforms, including the Tumor Microenvironment Specific Antibody Development Platform (LM-TME™), the Targeted Antibody Discovery Platform (LM-Abs™), the New Generation ADC Platform (LM-ADC™), and the T-cell Engager Platform (LM-TCE™). The acquisition will further enhance the Group's innovative R&D capabilities and accelerate the growth of the Group's innovative business. In addition, the LaNova Medicines’ outstanding and efficient R&D team will join the Group to further strengthen its innovation and R&D talent pool, ensuring the sustained delivery of high-quality innovation outcomes, and supporting the long term development of the Group’s innovation ecosystem.Looking ahead, the Group will remain focused on innovation, while enhancing R&D efficiency and quality across its four major therapeutic areas. The Group will also accelerate its progress of internationalization, thereby striving for rapid business expansion alongside steady performance improvement.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited is a leading Chinese pharmaceutical company continuing to invest in Oncology, Liver/Metabolic Diseases, Respiratory and Surgery/Analgesia, exploring innovative therapies to improve the lives of patients. The company has strong manufacturing capabilities and broad patient access across China. Sino Biopharmaceutical Limited is committed to bring innovation to address unmet healthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as a component of the MSCI Global Standard Index in China in 2013; In 2018, it was selected as a constituent stock of Hang Seng Index; In 2020, it was selected as a constituent stock of Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong Listed) 25 Index. The company has been listed in the “Top 50 Global Pharmaceutical Enterprises” published by the authoritative American magazine Pharmaceutical Manager for seven consecutive years, and has been rated as the “Top 50 Best Companies in Asia Pacific” by Forbes (Asia) for three consecutive years.For more information, please visit: www.sinobiopharm.com Copyright 2025 ACN Newswire via SeaPRwire.com.